Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Francesca Bruce
Following on from moves to push price transparency on to the global agenda, Italy is poised to pass a decree that would oblige companies to disclose public R&D funding.
A draft decree in Italy aims to put added therapeutic value at the centre of reimbursement decisions.
A new tool from the European Network For Health Technology Assessment to evaluate the quality of registries is now being piloted.
Austria’s health technology appraisal institute aims to further discussion on public investments in R&D and medicines pricing transparency.
The Scottish health technology appraisal body, the SMC, has okayed Gilead’s CAR-T therapy Yescarta for use on the Scottish National Health Service.
The Labour Party says it would overhaul the system for pricing medicines in the UK by de-linking innovation and price incentives if it gets into office at the next general election.